MedTrace Logo

Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis

NCT01357538 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2011-05-20

No results posted yet for this study

Summary

This is a multicentre, randomised, double-masked, parallel-group, phase IV comparison of Posiformin 2 % eye ointment (active substance: bibrocathol) in the treatment of blepharitis.

Conditions

  • Blepharitis
  • Signs and Symptoms

Interventions

DRUG

Posiformin 2 %, bibrocathol

A strip of 5 mm eye ointment applied 3 times per day to the eye lid

DRUG

Placebo Comparator

corresponding vehicle, eye ointment applied to the eye lid

Sponsors & Collaborators

  • Ursapharm Arzneimittel GmbH

    lead INDUSTRY

Principal Investigators

  • Pavel A Bezdetko, Prof. · Kharkov District Clinical Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-07-31
Completion
2009-08-31

Countries

  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01357538 on ClinicalTrials.gov